Promising phase 2B trial results of Lanifibranor in NASH
Hosts
Prof. Manuel Castro Cabezas
Scientific Officer
Manuel is a senior consultant for endocrinology, internal medicine, and vascular diseases at the Franciscus Gasthuis Rotterdam and associate professor of medicine at Erasmus Medical Center, Rotterdam, the Netherlands.
Hosts
Prof. dr. Christophe Moreno, M.D.
Scientific Officer
Christophe is a professor in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is an important consultant to the NASH Clinical team.
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno
Related webinars
Upcoming webinar: Why NASH trials frequently fail and how to improve them
The upcoming NASH clinical webinar promises to be an insightful and informative session, with our scientific officer Manuel Castro Cabezas as the guest speaker. Manuel will be sharing his expertise on the topic of "Why NASH trials frequently fa...
Getting GRIP on NASH: Implementation of an international screening program
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program. During this presentat...
NAFLD: patient identification strategies
In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...